Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIIA
Condition: Non Small Cell Lung Cancer Interventions: Drug: anti-PD-1 or anti-PD-L1; Drug: EGFR-TKI, ALK inhibitor, ROS1 inhibitor; Drug: investigator decided Sponsor: Shanghai Chest Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hospitals | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research